Overview

Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites

Status:
Unknown status

Trial end date:
2018-02-01

Target enrollment:

Participant gender:

Summary

This study makes an observation over the objective response rate of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination in the treatment of malignant ascites. All the participants will randomly receive the treatment of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination or convention drugs peritoneal perfusion and systemic therapy combination.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Hui ting Xu，MD

Treatments:

Methotrexate